Dr. Denise Johnson| Your Turn
Narcan carried by Erie Police to save lives
Erie Bureau of Police Lt. Anthony Talarico shows a portable naloxone kit, Nov. 7, 2016, at the police station in Erie. Naloxone is a medicine that reverses the effects of opioid overdoses, like those caused by heroin
Christopher Millette, Erie Times-News
Bringinghomea new baby is an exciting time for families, but it is also a significant life-changing experience that can cause stress for parents, caregivers and children. While all families benefit from support during the newborn stage, it is particularly important when the newborn has a health condition like Neonatal Abstinence Syndrome, or NAS.
NAS is a group of symptoms experienced by newborns who have been exposed to medications or substances during pregnancy. With symptoms ranging from excessive crying and crankiness to vomiting and trouble sleeping, managing the symptoms of this syndrome can be challenging for families. NAS can also impact an infant's development, so it is important for families to be connected to treatment and supportive services as soon as possible. This can be a difficult time when families deserve our compassion as well as the best support we can give.
More:Treat opioid use disorder and reduce maternal deaths by extending Medicaid postpartum
The treatment for babies born with this condition depends on the type and severity of symptoms that they are experiencing. Not all babies require lengthy hospital stays or medicines to help with NAS. A new parent can use The Eat, Sleep, Console (ESC) method, which focuses on the infant's ability to maintain the basic functions of eating, sleeping and consoling to help with symptoms of withdrawal. This approach emphasizes the relationship between mother and baby.And studies suggest it can decrease hospital stays and the need for medicine.
In the most recent report published by the Department of Health, there were 1,608 NAS cases reported by Pennsylvania hospitals and birthing facilities in 2019. The overall incidence rate across the state was 11.9 cases per 1,000 live births, a significant increase over the past two decades, and one public health officials are working to address.
More:Opioid crisis spurs Erie hospitals to help addicted pregnant women
The Wolf Administration remains committed to the fight against substance use and its impact on our fellow Pennsylvanians, especially our youngest residents. The department, in partnership with the Northwestern Pennsylvania NAS Coalition and Ohio Perinatal Quality Collaborative, developed a comprehensivetoolkitto walk families through their questions about NAS and let them know about the programs and services available to provide support to their infant and family.
Connecting families to health care and support is an important part of providing the necessary treatment to infants born with NAS. In addition to health care services that can be provided at birth, babies born with this health concern may be eligible for other special services. One example of a service that is available for diagnosed babies in Pennsylvania isEarly Intervention At-Risk Tracking, to help keep an eye out for any developmental delays.
In addition to connecting families to services, the Wolf Administration is working to better understand NAS in Pennsylvania. Hospitals and birthing facilities are required to report up to 28 days after birth all confirmed and probable cases in newborns who are showing symptoms of withdrawal due to prenatal exposure to opioids and other drugs whether via prescription, medical therapy or illegal use. By gathering this information, we can better understand the burden on families in Pennsylvania, identify high incidence areas to target interventions and reduce statewide incidence rates of NAS.
As we continue to fight substance use disorder across the commonwealth, we must remain steadfast in our efforts to provide needed services to infants born with NAS and their families. We must also take steps to prevent NAS by connecting individuals to treatment and reducing barriers to substance use treatment for all Pennsylvanians.
If you or someone you know is struggling with substance use, help is available. If you need assistance finding a treatment provider or funding for treatment, please call 1-800-662-HELP (4357) or contact yourlocal county drug and alcohol office. Additionally, the department is available to provide information to all families in Pennsylvania. For information and referrals related to the care of infants, please call our Healthy Baby Line at 1-800-986-BABY (2229).
Dr. Denise Johnson is the acting Pennsylvania Health Secretary and Pennsylvania Physician General.
Read more from the original source:
Babies born exposed to opioids and drugs need our support - GoErie.com
- Eye exercises for vertigo: Exercises to try at home - Medical News Today - January 6th, 2023
- EMDR therapy: Everything you need to know - Medical News Today - December 28th, 2022
- Eye floaters: What causes them, and what can you do? - Medical News Today - December 28th, 2022
- Eye care professional - Wikipedia - December 28th, 2022
- New gene therapy to treat rare eye disease now available in Alberta ... - December 28th, 2022
- Novaliq submits New Drug Application seeking approval for first-of-a-kind Dry Eye Disease Treatment CyclASol - PR Newswire - August 11th, 2022
- New research digs into the genetic drivers of heart failure, with an eye to precision treatments - STAT - August 11th, 2022
- Gamma Probe Device Market Trends, On-going Demand, Opportunities, Segmentation, and Forecast till 2031 - BioSpace - August 11th, 2022
- Centrifuge Market: Increasing Prevalence of Infectious Diseases to Drive the Market - BioSpace - August 3rd, 2022
- Myopic macular degeneration: What it is, and more - Medical News Today - July 17th, 2022
- Roche Wraps Week with a Bang, Touting Long-Term Breast Cancer, AMD Data - BioSpace - July 17th, 2022
- EyePoint Pharmaceuticals Announces Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment... - July 17th, 2022
- What Are These Things Floating in Front of My Eyes? - The Epoch Times - July 17th, 2022
- Adverum Biotechnologies Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After a Single IVT Injection of ADVM-022... - July 17th, 2022
- Retinoblastoma among children: Early detection and treatment are vital - The Financial Express - May 20th, 2022
- Perceive Biotherapeutics Appoints Anne E. Fung MD, as Chief Medical Officer to Drive Transformational Clinical Programs - PR Newswire - May 20th, 2022
- Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101 -... - May 20th, 2022
- How the Pandemic is Taking a Toll on Rhode Island's Front-Line Health Care Workers - Rhode Island Monthly - May 20th, 2022
- Myrtelle Enters into a Worldwide Exclusive License Agreement with Rescue Hearing to Develop and Commercialize Gene Therapy for the Treatment of... - May 20th, 2022
- Capsida, Adverum, Instil and Metagenomi Showcase Therapies at ASGCT - BioSpace - May 20th, 2022
- GenSight Biologics Announces Publication of a Study of the Impact of LHON Disease on the Lives of Patients and Relatives in Journal of... - May 20th, 2022
- How Diabetes can be a driver for High blood pressure and eventually leads to Hypertension - APN News - May 20th, 2022
- Daewoong Pharmaceutical and HanAll Biopharma Invest in Turn Biotechnologies to Expand Growth Initiative - Yahoo Finance - April 11th, 2022
- Christian group prepares legal challenge over conversion therapy ban - The Telegraph - April 11th, 2022
- PFE: 5 Global Healthcare Stocks to Buy as BofA Warns of a - StockNews.com - April 11th, 2022
- Adverum Biotechnologies Proceeds with IND Amendment for ADVM-022 Phase 2 Trial in Wet AMD After Receiving Requested Type C Meeting Feedback from the... - April 11th, 2022